Mesoblast Limited (MESO)
(Delayed Data from NSDQ)
$7.23 USD
+0.13 (1.83%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $7.20 -0.03 (-0.41%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
Mesoblast Limited (MESO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$4.00 | $4.00 | $4.00 | -43.66% |
Price Target
Only one analyst offered a short-term price target of $4.00 for Mesoblast Limited. This represents a decline of 43.66% from the last closing price of $7.10.
Analyst Price Targets (1 )
Broker Rating
Mesoblast Limited currently has an average brokerage recommendation (ABR) of 2.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, one is Strong Buy, representing 25% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/MESO.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.50 | 2.00 | 2.00 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/16/2024 | Not Identified | Not Identified | Strong Buy | Hold |
6/20/2024 | Maxim Group | Michael Okunewitch | Hold | Hold |
6/4/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
3/12/2024 | Piper Sandler | Edward A Tenthoff | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.50 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 4 |
Average Target Price | $4.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | NA |